Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
RCKT 
Rocket Pharmaceuticals Inc (RCKT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: RCKT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
18 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $7.43
1 Year Target Price $7.43
| 12 | Strong Buy |
| 5 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -11.28% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 329.11M USD | Price to earnings Ratio - | 1Y Target Price 7.43 |
Price to earnings Ratio - | 1Y Target Price 7.43 | ||
Volume (30-day avg) 18 | Beta 0.65 | 52 Weeks Range 2.19 - 22.01 | Updated Date 08/15/2025 |
52 Weeks Range 2.19 - 22.01 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.51 |
Earnings Date
Report Date 2025-08-07 | When - | Estimate -0.5622 | Actual -0.62 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -38.07% | Return on Equity (TTM) -69.65% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 82814806 | Price to Sales(TTM) - |
Enterprise Value 82814806 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -7.77 | Shares Outstanding 107904000 | Shares Floating 81097312 |
Shares Outstanding 107904000 | Shares Floating 81097312 | ||
Percent Insiders 3.06 | Percent Institutions 90.82 |
Upturn AI SWOT
Rocket Pharmaceuticals Inc
Company Overview
History and Background
Rocket Pharmaceuticals, Inc. was founded in 2015. It focuses on developing gene therapies for rare and devastating diseases with significant unmet medical needs. The company has evolved from focusing on specific rare diseases to building a broader platform of gene therapy technologies.
Core Business Areas
- Hematologic Malignancies: Develops gene therapies targeting hematologic malignancies like Fanconi Anemia and Leukocyte Adhesion Deficiency (LAD)-I.
- Cardiomyopathies: Develops gene therapies for severe heart conditions such as Danon Disease.
- Neurologic Diseases: Developing therapies for rare neurological disorders.
Leadership and Structure
The leadership team consists of key executives in research and development, clinical operations, and business development. The company has a typical biopharmaceutical structure with departments focusing on research, clinical trials, manufacturing, and commercialization.
Top Products and Market Share
Key Offerings
- RP-L102 (Fanconi Anemia Group A): An ex vivo gene therapy currently in clinical trials for Fanconi Anemia Group A (FA-A). Market share data is not yet available as the product is not yet approved. Competitors include companies developing alternative therapies for FA, such as supportive care and hematopoietic stem cell transplantation.
- RP-L201 (LAD-I): An ex vivo gene therapy in clinical trials for Leukocyte Adhesion Deficiency-I (LAD-I). Market share data is unavailable due to the therapy being in development. Competitors are those providing current standard of care, like bone marrow transplants.
- RP-A501 (Danon Disease): An in vivo adeno-associated virus (AAV)-based gene therapy in clinical trials for Danon Disease. Market share is unavailable due to developmental stage. Competitors include those focusing on symptomatic management and heart transplantation.
Market Dynamics
Industry Overview
The gene therapy industry is experiencing significant growth, driven by advancements in vector technology and increasing regulatory acceptance. There's a high demand for effective treatments for rare genetic diseases.
Positioning
Rocket Pharmaceuticals is positioned as a leading company in the development of gene therapies for rare diseases, with a focus on hematologic malignancies, cardiomyopathies, and other severe disorders. Their competitive advantage lies in their diversified pipeline and experienced team.
Total Addressable Market (TAM)
The total addressable market for gene therapies is estimated to be in the tens of billions of dollars. Rocket Pharma is positioned to capture a portion of this TAM by focusing on indications with high unmet need and limited treatment options.
Upturn SWOT Analysis
Strengths
- Strong pipeline of gene therapy candidates
- Experienced management team
- Focus on rare and unmet medical needs
- Advanced gene therapy technology platform
Weaknesses
- High research and development costs
- Regulatory approval risks
- Manufacturing complexities
- Reliance on clinical trial success
Opportunities
- Expansion of pipeline into new disease areas
- Strategic partnerships and collaborations
- Accelerated regulatory pathways for rare diseases
- Potential for breakthrough therapy designations
Threats
- Competition from other gene therapy companies
- Adverse clinical trial results
- Changes in regulatory landscape
- Pricing and reimbursement challenges
Competitors and Market Share
Key Competitors
- BLUE
- CRSP
- EDIT
Competitive Landscape
Rocket Pharmaceuticals faces competition from established gene therapy companies with broader pipelines and greater resources. Their focus on specific rare diseases gives them a niche advantage, but they need to successfully navigate regulatory hurdles and manufacturing challenges to compete effectively.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is dependent on clinical trial progress and future product launches. Data not readily available.
Future Projections: Future projections rely on analyst estimates, requiring a financial data service.
Recent Initiatives: Recent initiatives include advancing clinical trials for RP-L102, RP-L201, and RP-A501 and expanding their manufacturing capabilities.
Summary
Rocket Pharmaceuticals is a clinical-stage biotechnology company focused on developing gene therapies for rare diseases. Its pipeline has shown promise. They are in a space with much promise and potential reward. RCKT is considered a smaller fish in the gene therapy ocean, it is unknown if they will thrive, get bought out, or fail. Their path forward is highly uncertain due to a lack of revenue at this stage of the company.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share data is estimated and may not be precise. Investing in biopharmaceutical companies involves significant risks.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Rocket Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Cranbury, NJ, United States | ||
IPO Launch date 2015-02-18 | CEO & Director Dr. Gaurav D. Shah M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 299 | Website https://www.rocketpharma.com |
Full time employees 299 | Website https://www.rocketpharma.com | ||
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases in the United States. It develops vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), which is in phase 1; and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is a form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart, which is in preclinical stage. It also develops vivo lentiviral (LV) programs, which include programs for Leukocyte Adhesion Deficiency-I (LAD-I), a genetic disorder that causes the immune system to malfunction (RP-L201); Fanconi Anemia (FA), a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells (RP-L102); and Pyruvate Kinase Deficiency (PKD), a red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia (RP-L301). It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; REGENXBIO, Inc.; and Temple University. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.